JPMorgan upgraded G1 Therapeutics to Neutral from Underweight with a $7.15 price target and Pharmacosmos agreed to acquire G1. The acquisition price of $7.15 for a deal value of $405M represents a 68% premium to the most recent closing price and the deal is expected to close in late Q3, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GTHX:
- G1 Therapeutics Acquisition and Executive Compensation Revamp
- Pharmacosmos Group to Acquire G1 Therapeutics
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
- G1 Therapeutics added to Russell 2000, 3000 Indexes